Citations

Showing 10 of 108162 citations.

Replication and cross-validation of the personality assessment inventory (PAI) cognitive bias scale (CBS) in a mixed clinical sample
Boress, Kaley , Gaasedelen, Owen J., Croghan, Anna, Johnson, Marcie King, Caraher, Kristen , Basso, Michael R. , Whiteside, Douglas M. , Whiteside, Douglas

Mayo Clinic

The Clinical Neuropsychologist | February 22, 2021 | Volume: 36 | Issue: 7 | Pages: 1860-1877

10.1080/13854046.2021.1889681 | PMID 33612093 Get It

All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections
Hoenigl, Martin , Schuetz, Audrey N. , Zhang, Sean X. , Cornely, Oliver A. , Schuetz, Audrey N , Zhang, Sean X , Cornely, Oliver A , Hoenigl, Martin , Levitz, Stuart M.

Mayo Clinic

mBio | February 22, 2021 | Volume: 12 | Issue: 1 | Pages: No page available

10.1128/mbio.02920-20 | PMID 33622731 Get It

Invasive mold infections caused by molds other than Aspergillus spp. or Mucorales are emerging. The reported prevalences of infection due to these rare fungal pathogens vary among geographic regions, driven by differences in climatic conditions, susceptible hosts, and diagnostic capabilities.
Detection of Tick-Borne Bacteria from Whole Blood Using 16S Ribosomal RNA Gene PCR Followed by Next-Generation Sequencing
Rodino, Kyle G. , Sheldon, Sarah W., Kingry, Luke C. , Petersen, Jeannine M., Patel, Robin , Pritt, Bobbi S. , Wolf, Matthew J, Kingry, Luke , Patel, Robin , Pritt, Bobbi S , Wolf, Matthew J.

Mayo Clinic

Journal of Clinical Microbiology | February 22, 2021 | Volume: 59 | Issue: 5 | Pages: No page available

10.1128/jcm.03129-20 | PMID 33627320 Get It

Reported cases of tick-borne diseases have steadily increased for more than a decade. In the United States, a majority of tick-borne infections are caused by bacteria.
Photocrosslinked Bioreducible Polymeric Nanoparticles for Enhanced Systemic siRNA Delivery as Cancer Therapy
Karlsson, Johan , Tzeng, Stephany Y. , Hemmati, Shayan, Luly, Kathryn M , Choi, Olivia, Rui, Yuan , Wilson, David R. , Kozielski, Kristen , Quiñones‐Hinojosa, Alfredo , Green, Jordan J. , Green, Jordan J , Tzeng, Stephany Y , Choi, Olivia

Mayo Clinic

Advanced Functional Materials | February 22, 2021 | Volume: 31 | Issue: 17 | Pages: No page available

10.1002/adfm.202009768 | PMID 34650390 Get It

AbstractClinical translation of polymer‐based nanocarriers for systemic delivery of RNA has been limited due to poor colloidal stability in the blood stream and intracellular delivery of the RNA to the cytosol. To address these limitations, this study reports a new strategy incorporating photocrosslinking of bioreducible nanoparticles for improved stability extracellularly and rapid release of RNA intracellularly. In this design, the polymeric nanocarriers contain ester bonds for hydrolytic degradation and disulfide bonds for environmentally triggered small interfering RNA (siRNA) release in the cytosol. These photocrosslinked bioreducible nanoparticles (XbNPs) have a shielded surface charge, reduced adsorption of serum proteins, and enable superior siRNA‐mediated knockdown in both glioma and melanoma cells in high‐serum conditions compared to non‐crosslinked formulations. Mechanistically, XbNPs promote cellular uptake and the presence of secondary and tertiary amines enables efficient endosomal escape. Following systemic administration, XbNPs facilitate targeting of cancer cells and tissue‐mediated siRNA delivery beyond the liver, unlike conventional nanoparticle‐based delivery. These attributes of XbNPs facilitate robust siRNA‐mediated knockdown in vivo in melanoma tumors colonized in the lungs following systemic administration. Thus, biodegradable polymeric nanoparticles, via photocrosslinking, demonstrate extended colloidal stability and efficient delivery of RNA therapeutics under physiological conditions, and thereby potentially advance systemic delivery technologies for nucleic acid‐based therapeutics.
Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities
Mehta, Dev , Garza, Ivan , Robertson, Carrie E. , Mehta, Dev G , Robertson, Carrie E

Mayo Clinic

Cephalalgia | February 22, 2021 | Volume: 41 | Issue: 9 | Pages: 1015-1026

10.1177/0333102421996355 | PMID 33615842 Get It

Objective To review characteristics and outcomes of all cases of visual snow seen at our institution, with attention to possible triggering events or comorbidities. Methods This is a retrospective case series of patients seen at our tertiary care center from January 1994 to January 2020. Charts were reviewed if they contained the term “visual snow”. Results Of the 449 charts reviewed, 248 patients described seeing visual snow in part or all of their vision. Thirty-eight reported transient visual snow as their typical migraine aura. Of the remaining 210 patients, 89 were reported to have either an inciting event or contributing comorbidity for their visual snow symptoms, including: Post-concussion (n = 15), dramatic change in migraine or aura (n = 14), post-infection (n = 13), hallucinogen persisting perception disorder (n = 10), ocular abnormalities (n = 7), idiopathic intracranial hypertension (n = 4), neoplastic (n = 1), and posterior cortical atrophy (n = 1). Some patients had partial improvement with benzodiazepines (n = 6), lamotrigine (n = 5), topiramate (n = 3) and acetazolamide (n = 3). Presenting characteristics were similar, but patients with visual snow attributed to an inciting event or contributing comorbidity were more likely to have some improvement in their symptoms by last follow-up compared to spontaneous visual snow ( p < .001). Conclusions Though most cases of visual snow are spontaneous, potential secondary causes should be recognized by clinicians. Patients who develop visual snow after an inciting event or related to an underlying comorbidity may have a better prognosis than those in whom it develops spontaneously. In select cases, treatment of the suspected underlying cause may significantly alleviate the otherwise typical intractable visual disturbances associated with visual snow.
CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache
Kopruszinski, Caroline Machado , Turnes, Joelle M., Swiokla, Juliana, Weinstein, Troy, Anderson, Trent , Navratilova, Edita , Kopruszinski, Caroline , Navratilova, Edita , Schwedt, Todd J. , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | February 22, 2021 | Volume: 41 | Issue: 6 | Pages: 749-759

10.1177/0333102420981688 | PMID 33615840 Get It

Aim Determine the role of calcitonin-gene related peptide in promoting post-traumatic headache and dysregulation of central pain modulation induced by mild traumatic brain injury in mice. Methods Mild traumatic brain injury was induced in lightly anesthetized male C57BL/6J mice by a weight drop onto a closed and unfixed skull, which allowed free head rotation after the impact. We first determined possible alterations in the diffuse noxious inhibitory controls, a measure of net descending pain inhibition called conditioned pain modulation in humans at day 2 following mild traumatic brain injury. Diffuse noxious inhibitory control was assessed as the latency to a thermally induced tail-flick that served as the test stimulus in the presence of right forepaw capsaicin injection that provided the conditioning stimulus. Post-traumatic headache-like behaviors were assessed by the development of cutaneous allodynia in the periorbital and hindpaw regions after mild traumatic brain injury. We then determined if intraperitoneal fremanezumab, an anti-calcitonin-gene related peptide monoclonal antibody or vehicle administered 2 h after sham or mild traumatic brain injury induction could alter cutaneous allodynia or diffuse noxious inhibitory control responses on day 2 post mild traumatic brain injury. Results In naïve and sham mice, capsaicin injection into the forepaw elevated the latency to tail-flick, reflecting the antinociceptive diffuse noxious inhibitory control response. Periorbital and hindpaw cutaneous allodynia, as well as a loss of diffuse noxious inhibitory control, was observed in mice 2 days after mild traumatic brain injury. Systemic treatment with fremanezumab blocked mild traumatic brain injury-induced cutaneous allodynia and prevented the loss of diffuse noxious inhibitory controls in mice subjected to a mild traumatic brain injury. Interpretation Sequestration of calcitonin-gene related peptide in the initial stages following mild traumatic brain injury blocked the acute allodynia that may reflect mild traumatic brain injury-related post-traumatic headache and, additionally, prevented the loss of net descending inhibition within central pain modulation pathways. As loss of conditioned pain modulation has been linked to multiple persistent pain conditions, dysregulation of descending modulatory pathways may contribute to the persistence of post-traumatic headache. Additionally, evaluation of the conditioned pain modulation/diffuse noxious inhibitory controls response may serve as a biomarker of vulnerability for chronic/persistent pain. These findings suggest that early anti-calcitonin-gene related peptide intervention has the potential to be effective both for the treatment of mild traumatic brain injury-induced post-traumatic headache, as well as inhibiting mechanisms that may promote post-traumatic headache persistence.
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)
Kasper, Bernd , Achee, Annie, Schuster, Kathrin , Wilson, Roger , Oortmerssen, G. van , Gladdy, Rebecca A. , Hemming, Matthew L. , Huang, Paul H. , Jones, Robin L. , Sanfilippo, Roberta , Schuetze, Scott M. , Somaiah, Neeta , Tine, Brian A. Van , Okuno, Scott H. , Trent, Jonathan C. , Jones, Robin L , Van Tine, Brian A , Trent, Jonathan , Ingham, Matthew , Pollack, Seth M. , Reinke, Denise K. , Wilky, Breelyn A

Mayo Clinic

Cancers | February 21, 2021 | Volume: 13 | Issue: 4 | Pages: 886

10.3390/cancers13040886 | PMID 33672607 Get It

As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.
Quality‐of‐life instruments in endoscopic endonasal skull base surgery—A practical systematic review
Shukla, Aishwarya , Ahmed, Omar G. , Orlov, Cinthia P., Price, Carrie , Mukherjee, Debraj , Rowan, Nicholas R. , Choby, Garret , Rowan, Nicholas R , Mukherjee, Debraj , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | February 21, 2021 | Volume: 11 | Issue: 8 | Pages: 1264-1268

10.1002/alr.22783 | PMID 33611853 Get It

Exertional Painless Weakness: Chronic Inflammatory Demyelinating Polyradiculoneuropathy in a Recreational Runner
Rosario‐Concepción, Raúl A. , Pagan‐Rosado, Robert , Pagán-Rosado, Robert D

Mayo Clinic

Current Sports Medicine Reports | February 21, 2021 | Volume: 20 | Issue: 2 | Pages: 76-79

10.1249/jsr.0000000000000805 | PMID 33560029 Get It

Systematic review of outcomes and endpoints in acute migraine clinical trials
McGinley, James S., Nishida, Tracy K., Buse, Dawn C. , Goadsby, Peter J. , Goadsby, Peter J , Houts, Carrie R. , Wirth, Robert J. , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 21, 2021 | Volume: 61 | Issue: 2 | Pages: 263-275

10.1111/head.14067 | PMID 33611818 Get It

Abstract Background/Objective To review the acute migraine clinical trial literature and provide a summary of the endpoints and outcomes used in such trials. Method A systematic literature review, following a prespecified (but unregistered) protocol developed to adhere to recommendations of the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses, was conducted to understand endpoints and outcomes used in acute migraine clinical trials. Predefined terms were searched in PubMed to locate clinical trials assessing acute migraine treatments. Final database search was conducted on October 28, 2019. Identified publications were reviewed against established inclusion and exclusion criteria to determine eligibility. Data related to general trial design characteristics, sample characteristics, and outcomes and endpoints reported in each publication were extracted from eligible publications. Descriptive summaries of design features, sample characteristics, and the endpoints and outcomes employed across publications were constructed. Outcomes are presented within four broad categories: (a) pain‐related outcomes (pain relief, pain freedom, etc.), (b) associated symptoms (nausea, photophobia, etc.), (c) disability/impairment/impact, (d) patient‐reported outcome measures (PROMs, general health and migraine/headache‐specific). Endpoint types were categorized within three broad categories: (a) change from baseline, (b) fixed timepoint, and (c) responder definitions (e.g., 50% reduction). This review focuses on a subset of recent (1998 or later) randomized and blinded publications evaluating drugs or medical devices. Results Of 1567 publications found through the initial search and reference section reviews, 705 met criteria and were included for data extraction. Inter‐rater agreement kappas for the descriptive variables extracted had an average kappa estimate of 0.86. The more recent, randomized and blinded pharmaceutical and medical device article subset includes 451 publications (451/705, 63.9%). The outcomes and endpoints varied substantially across trials, ranging from pain relief or freedom, freedom from or relief of migraine‐associated symptoms, use of acute or rescue medication, and various other PROMs, including measures of satisfaction and quality of life. Within the recent randomized and blinded article subset, most articles examined ≥1 pain‐related outcome (430/451, 95.3%). Of the publications that examined pain, outcomes most often used were pain relief (310/430, 72.1%), pain freedom (279/430, 64.9%), and headache recurrence (202/43,051, 47.0%) or rescue medication use (278/430, 64.9%). Associated symptoms such as nausea, photophobia, and phonophobia were more frequently measured (299/451, 66.3%) compared to most bothersome associated symptom (16/451, 3.5%), as it is a new addition to regulatory guidance. Over one‐third of eligible publications examined disability/impairment (186/451, 41.2%) or ≥1 PROM (159/451, 35.3%). The definition of the endpoints used (e.g., change from baseline, fixed timepoint comparisons, categorization of “responders” to treatment based on wide variety of “responder definitions”) also differed substantially across publications. Conclusion Acute migraine clinical trials exhibit a large amount of variability in outcomes and endpoints used, in addition to the variability in how outcomes and endpoints were used from trial‐to‐trial. There were some common elements across trials that align with guidance from the International Headache Society, the Food and Drug Administration and other regulatory agencies (e.g., assessing pain and associated symptoms, 2‐hour post‐treatment). Other aspects of acute migraine clinical trial design did not follow guidance. For example, multi‐item PROMs intended to measure constructs (e.g., scales) are rarely used, the use of pain‐related outcomes is inconsistent, some associated symptom assessments are idiosyncratic, and the timing of the assessment of primary endpoints is variable. The development of a core set of outcomes and endpoints for acute migraine clinical trials that are patient‐centered and statistically robust could improve the conduct of individual trials, facilitate cross‐trial comparisons, and better support informed treatment decisions by healthcare professionals and patients.